×
Centessa Pharmaceuticals EBIT 2021-2024 | CNTA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Centessa Pharmaceuticals ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Centessa Pharmaceuticals EBIT 2021-2024 | CNTA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Centessa Pharmaceuticals ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$42.6B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.1B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$14B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12B
Catalent (CTLT)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.2B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.6B
Evotec AG (EVO)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Harrow (HROW)
$1.5B
Indivior (INDV)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B
ARS Pharmaceuticals (SPRY)
$1.4B